Show simple item record

dc.contributor.authorDallal Bashi, Y.H.
dc.contributor.authorAli, A.
dc.contributor.authorAl Ayoub, Y.
dc.contributor.authorAssi, Khaled H.
dc.contributor.authorMairs, R.
dc.contributor.authorMcCarthy, H.O.
dc.contributor.authorTunney, M.M.
dc.contributor.authorKett, V.L.
dc.date.accessioned2024-10-23T10:19:33Z
dc.date.available2024-10-23T10:19:33Z
dc.date.issued2024-03-25
dc.identifier.citationDallal Bashi YH, Ali A, Al Ayoub Y et al (2024) Inhaled dry powder liposomal azithromycin for treatment of chronic lower respiratory tract infection. International Journal of Pharmaceutics. 653: 123841.en_US
dc.identifier.urihttp://hdl.handle.net/10454/20085
dc.descriptionYesen_US
dc.description.abstractA dry powder inhaled liposomal azithromycin formulation was developed for the treatment of chronic respiratory diseases such as cystic fibrosis and bronchiectasis. Key properties including liposome size, charge and encapsulation efficiency powder size, shape, glass transition temperature (Tg), water content and in vitro respiratory deposition were determined. Antimicrobial activity against cystic fibrosis (CF) respiratory pathogens was determined by MIC, MBC and biofilm assays. Cytotoxicity and cellular uptake studies were performed using A549 cells. The average liposome size was 105 nm, charge was 55 mV and encapsulation efficiency was 75 %. The mean powder particle size d[v,50] of 4.54 µm and Mass Median Aerodynamic Diameter (MMAD) was 5.23 µm with a mean Tg of 76˚C and water content of 2.1 %. These excellent physicochemical characteristics were maintained over one year. Liposomal loaded azithromycin demonstrated enhanced activity against P. aeruginosa clinical isolates grown in biofilm. The formulation was rapidly delivered into bacterial cells with > 75 % uptake in 1 h. Rapid uptake into A549 cells via a cholesterol-dependent endocytosis pathway with no cytotoxic effects apparent. These data demonstrate that this formulation could offer benefits over current treatment regimens for people with chronic respiratory infection.en_US
dc.language.isoenen_US
dc.rights(c) 2024 The Authors. This is an Open Access article distributed under the Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/)en_US
dc.subjectLiposomeen_US
dc.subjectAzithromycinen_US
dc.subjectSpray dryingen_US
dc.subjectDry powder inhaleren_US
dc.subjectRespiratory infectionen_US
dc.subjectCystic fibrosisen_US
dc.titleInhaled dry powder liposomal azithromycin for treatment of chronic lower respiratory tract infectionen_US
dc.status.refereedYesen_US
dc.date.application2024-01-23
dc.typeArticleen_US
dc.type.versionPublished versionen_US
dc.identifier.doihttps://doi.org/10.1016/j.ijpharm.2024.123841en_US
dc.rights.licenseCC-BYen_US
refterms.dateFOA2024-10-23T10:19:33Z
dc.openaccess.statusopenAccessen_US
dc.date.endofembargoTest
dc.date.accepted2024-01-20


Item file(s)

Thumbnail
Name:
dallal-bashi_et_al_2024.pdf
Size:
6.523Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record